Abstract
Background The Cancer Stem Cells (CSCs) hypothesis proposes that malignant brain tumours are organized into aberrant cell hierarchies where a subset of parent CSCs replicate asymmetrically and unlimitedly to produce differentiated daughter cell [1,2]. These parent CSCs are highly adaptive and resistant to the chemotherapeutic drugs [3]. Developing new drugs that target CSCs requires a comprehensive understanding of the pharmacogenomics behavior of these cells [4,5]. Such understanding requires reliable in vitro and in vivo models that represent the beneficial patients. This project is set out to: i) Establish a collection of astrocytoma cell lines generated from Saudi patients, ii) Select drug resistant brain tumour CSCs, iii) Characterize drug resistant brain tumour CSCs individually, and iv) Deduce common features for drug resistant brain tumour CSCs.
Highlights
The Cancer Stem Cells (CSCs) hypothesis proposes that malignant brain tumours are organized into aberrant cell hierarchies where a subset of parent CSCs replicate asymmetrically and unlimitedly to produce differentiated daughter cell [1,2]
Optimisation of the clonogenic selection assay and immunostaining for cancer stem cells markers are under progress
Further work is required for the characterization of the drug resistant cancer stem cell component within these cell lines
Summary
The Cancer Stem Cells (CSCs) hypothesis proposes that malignant brain tumours are organized into aberrant cell hierarchies where a subset of parent CSCs replicate asymmetrically and unlimitedly to produce differentiated daughter cell [1,2] These parent CSCs are highly adaptive and resistant to the chemotherapeutic drugs [3]. Developing new drugs that target CSCs requires a comprehensive understanding of the pharmacogenomics behavior of these cells [4,5]. Such understanding requires reliable in vitro and in vivo models that represent the beneficial patients. Optimisation of the clonogenic selection assay and immunostaining for cancer stem cells markers are under progress
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have